An Interdisciplinary Atlas and Manual

Bearbeitet von
Wolfgang Mohnike, Gustav Hör, Heinrich R Schelbert

ISBN 978 3 540 74090 2
Format (B x L): 20,3 x 27,6 cm

Weitere Fachgebiete > Medizin > Sonstige Medizinische Fachgebiete > Nuklearmedizin, Radiotherapie

schnell und portofrei erhältlich bei beck-shop.de
## Contents

### 1 Introduction –
**Positron Emission Tomography: Past and Present**

1.1 **Survey**
- Physical and Biochemical Fundamentals
- PET in National and International Medical Care Systems

1.2 **Technological Variants and Developments**
- Coincidence PET vs. Dedicated PET
- Differentiated PET Evaluation
- PET/CT – a New Key Technology
- Influence of PET/CT on PET
- Studies Dealing with the Cost Efficiency of PET Alone
- PET/CT or Comparison of Co-Registered Findings?
- “Standard” (CARE)-CT and PET/CT
- American Joint Committee on Cancer Screening in Japan and Taiwan

1.3 **Increased FDG Uptake Due to Physiological and Technical Factors**

1.4 **References**

### 2 Fundamentals

**THOMAS BEYER**

2.1 **Preface**
- Positron Emission Tomography (PET)
- Radioisotopes and PET Tracers
- Coincidence Measurement and Quantification
- PET Measurement Results and Reconstruction
- PET Scanners and Scintillation Detectors

2.2 **Combined PET/CT**
- Retrospective Image Fusion
- The PET/CT Prototype
- CT-Based Attenuation Correction
- Commercialization of PET/CT
- New Technical Developments in PET/CT
- PET/CT Acquisition Protocols
- Sources of Errors and Optimization Options
- Radiation Protection Aspects

2.3 **Conclusion**

2.4 **References**

### 3 Pneumology

#### 3.1 Bronchial Carcinoma (BC)

#### 3.2 Significance of FDG-PET in Diagnostic and Therapeutic Management
- Critical Evaluation of Diagnosis Management

#### 3.3 Guidelines for 18F-FDG-PET Indications

#### 3.4 Technical and Biochemical Factors
- Is Coincidence PET Equivalent to Full-Ring PET?
- PET as Metabolism and Proliferation Marker
- Innovative Radiopharmacy

#### 3.5 Special PET Indications
- False-Negative PET
- False-Positive PET
- How Useful Is Integrated PET/CT?

#### 3.6 SCLC (Small-Cell Lung Cancer)

#### 3.7 Pleural Processes
- Malignant Pleural Tumours (Mesothelioma)
- Imaging Methods

#### 3.8 Case Studies
- Scar Carcinoma of the Lung
- Pneumonia
- Lymph Node Metastases of a Squamous Cell Carcinoma
- Metastasized Bronchial Carcinoma
- Round Focus in the Lung
- Metastasized Bronchial Carcinoma
- Metastasized Adenocarcinoma in the Left Lower Lobe of the Lung
- Downstaging of a Squamous Cell Carcinoma of the Lung
- Preoperative Staging of a Bronchial Carcinoma
- Pleural Carcinosis after Pneumectomy
- Recurrence of a Brain Metastasis
- Pleural Mesothelioma
- Prevention of Non-Curative Thoracic Surgery
- Upstaging of a Bronchial Carcinoma
- Bilateral Metastases of an NSCLC in the Suprarenal Glands

3.9 **References**

---

---
### 4 Gastroenterology

#### 4.1 Introduction
- Molecular Strategy
- Metabolic Influencing Factors
- PET Screening!
- Incidentally Detected Lesions (IDL)

#### 4.2 Oesophageal Carcinoma
- PET in Diagnosis Management of Oesophageal Carcinoma

#### 4.3 Gastric Carcinoma
- MALT Lymphomas

#### 4.4 Colorectal Carcinomas
- Treatment
- Status of PET
- PET/CT as the Optimum
- PET Indications
- Limitations of PET
- Artefacts
- FDG-PET
- Alternative and Adjuvant Markers
- Synopsis

#### 4.5 Liver and Biliary Tract Carcinomas

#### 4.6 Gastrointestinal Stromal Tumours

#### 4.7 Pancreas Carcinomas
- Imaging
- Curative Treatment
- New Gene-Based Treatment Strategies
- Indications
- DGN Classes, Consequences
- Impact of SUVs on Survival Time
- False-Negative/-Positive PET Findings
- Pancreas NETs (Neuroendocrine Tumours)

#### 4.8 Neuroendocrine Tumours (NETs) of the Gastrointestinal Tract
- Carcinoids
- Conventional Diagnostics
- NET Spectrum
- Biochemistry
- High Secretors
- Low (Non-)Secretors
- Limitations of PET

#### 4.9 Case Studies

<table>
<thead>
<tr>
<th>Patient</th>
<th>Diagnosis</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oesophageal Carcinoma</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>Lymph Node Metastasis of an Oesophageal Carcinoma</td>
<td>103</td>
</tr>
<tr>
<td>3</td>
<td>Downstaging of an Oesophageal Carcinoma</td>
<td>105</td>
</tr>
<tr>
<td>4</td>
<td>Carcinoma of the Head of the Pancreas</td>
<td>107</td>
</tr>
<tr>
<td>5</td>
<td>Metastasized Carcinoma of the Head of the Pancreas</td>
<td>110</td>
</tr>
<tr>
<td>6</td>
<td>Carcinoma of the Body of the Pancreas</td>
<td>112</td>
</tr>
<tr>
<td>7</td>
<td>Hepatocellular Carcinoma with Multiple Metastases</td>
<td>114</td>
</tr>
<tr>
<td>8</td>
<td>Gastric Carcinoma</td>
<td>117</td>
</tr>
<tr>
<td>9</td>
<td>Leiomyoma of the Stomach</td>
<td>118</td>
</tr>
<tr>
<td>10</td>
<td>Follow-Up of an Adenocarcinoma of the Stomach</td>
<td>121</td>
</tr>
<tr>
<td>11</td>
<td>Staging of an Adenocarcinoma of the Stomach</td>
<td>123</td>
</tr>
<tr>
<td>12</td>
<td>Staging of a Carcinoma of the Corpus of the Stomach</td>
<td>124</td>
</tr>
<tr>
<td>13</td>
<td>Lymph Node Metastasis from Gastric Carcinoma</td>
<td>126</td>
</tr>
<tr>
<td>14</td>
<td>Extended Metastatic Spread to the Liver from Adenocarcinoma of the Stomach</td>
<td>128</td>
</tr>
<tr>
<td>15</td>
<td>Caecum Carcinoma</td>
<td>130</td>
</tr>
<tr>
<td>16</td>
<td>Carcinoma of the Colon Ascendens</td>
<td>132</td>
</tr>
<tr>
<td>17</td>
<td>T1 Carcinoma of the Colon</td>
<td>134</td>
</tr>
<tr>
<td>18</td>
<td>Adenocarcinoma of the Sigmoid Colon</td>
<td>136</td>
</tr>
<tr>
<td>19</td>
<td>Liver Metastasis of a Colon Carcinoma</td>
<td>138</td>
</tr>
<tr>
<td>20</td>
<td>Lymphoma Conglomerate</td>
<td>140</td>
</tr>
<tr>
<td>21</td>
<td>Lung Metastasis</td>
<td>142</td>
</tr>
<tr>
<td>22</td>
<td>Pulmonary, Hepatic and Lymphogenic Metastatic Spread Following Sigmoid Carcinoma</td>
<td>144</td>
</tr>
<tr>
<td>23</td>
<td>Metastasized Sigmoid Carcinoma</td>
<td>146</td>
</tr>
<tr>
<td>24</td>
<td>Peritoneal Carcinosis and Ascites</td>
<td>148</td>
</tr>
<tr>
<td>25</td>
<td>Lung Metastasis Following Sigmoid Carcinoma</td>
<td>150</td>
</tr>
<tr>
<td>26</td>
<td>Liver Metastasis Following Sigmoid Carcinoma</td>
<td>153</td>
</tr>
<tr>
<td>27</td>
<td>Lymph Node Metastasis</td>
<td>156</td>
</tr>
<tr>
<td>28</td>
<td>Metastatic Spread to the Liver</td>
<td>158</td>
</tr>
<tr>
<td>29</td>
<td>Liver and Lung Metastases</td>
<td>160</td>
</tr>
<tr>
<td>30</td>
<td>Rectal Carcinoma with Lymph Node Metastases</td>
<td>163</td>
</tr>
<tr>
<td>31</td>
<td>Suprarenal and Lung Metastases</td>
<td>166</td>
</tr>
<tr>
<td>32</td>
<td>Lung and Bone Metastases</td>
<td>168</td>
</tr>
<tr>
<td>33</td>
<td>Suprarenal Metastasis of a Rectal Carcinoma</td>
<td>169</td>
</tr>
<tr>
<td>34</td>
<td>Restaging of a Rectal Carcinoma</td>
<td>172</td>
</tr>
<tr>
<td>35</td>
<td>Suprarenal and Lung Metastases Associated with Rectal Carcinoma</td>
<td>174</td>
</tr>
<tr>
<td>36</td>
<td>Restaging of a Rectal Carcinoma</td>
<td>176</td>
</tr>
<tr>
<td>37</td>
<td>Local Recurrence and Liver Metastases of a Rectal Carcinoma</td>
<td>178</td>
</tr>
<tr>
<td>38</td>
<td>Extended Metastatic Spread of a Mesenterial Conglomerate Tumour</td>
<td>181</td>
</tr>
<tr>
<td>39</td>
<td>GIST Tumour with Liver Involvement</td>
<td>183</td>
</tr>
<tr>
<td>40</td>
<td>Malignoma in the Left Epigastric Region</td>
<td>184</td>
</tr>
</tbody>
</table>
5 Gynaecology .......................... 205

5.1 Introduction .......................... 206
The Importance of Nuclear Medical Methods .......................... 206

5.2 Breast Cancers ........................ 206
Mammography .......................... 207
Tumour Markers .......................... 208
CT and MRI .............................. 208
18F-Fluoride PET ......................... 209
SPECT ................................. 209
Sentinel Node Scintigraphy (SNS) ............... 209
Positron Emission Tomography ................. 209
Preoperative Axillary Staging .................. 210
Extra-Axillary Metastases .................... 211
Treatment Monitoring ..................... 211
Potentials and Limitations of PET ............ 211
Special Neuro-Oncological Problems/Pitfalls .. 212
PET Screening? .......................... 212
Risk Stratification ....................... 212
PET/CT ............................... 212
Assessment of the Bone Status .......... 212
18F-Fluoride PET ............................ 212
Diagnostic Imaging of the Breast: Indications 212

5.3 Ovarian Cancer ...................... 213
Tumour Types .......................... 213
Conventional Diagnostics .................. 213
PET ...................................... 213

5.4 Peritoneal Cancer (PC) .............. 215

5.5 Cervical Cancer ...................... 215
PET Diagnostics .......................... 215

5.6 Case Studies ......................... 216
Patient 1 Lymph Node Metastasis with Status Post Carcinoma of the Right Breast and Ovarian Carcinoma on Both Sides .......... 216
Patient 2 Inflammatory Breast Cancer ....... 218
Patient 3 Breast Cancer with Osseous Metastases ............... 220
Patient 4 Preoperative Staging of a Breast Cancer ............... 222

5.7 References .......................... 298
6 Urology ........................................ 303
6.1 Introduction .................................. 303
6.2 Renal Malignancies .......................... 304
   Introduction .................................. 304
   Diagnostics ................................. 304
6.3 Adrenal Tumours ............................ 305
   Imaging Diagnostics ....................... 305
6.4 Bladder Carcinoma .......................... 305
   Status of PET .............................. 306
6.5 Prostate Carcinoma .......................... 306
   Introduction ................................ 306
   Diagnostics .................................. 306
   Treatment ................................... 309
   Status of Individual Imaging Methods ....... 309
6.6 Germ Cell Tumours .......................... 313
   Introduction ................................ 313
   PET Study Situation ....................... 314
6.7 Penis Carcinoma .............................. 315
6.8 Case Studies .................................. 316
   Patient 1 Malignoma of the Base of the Bladder 316
   Patient 2 Malignoma of the Posterior Wall of the Bladder 318
   Patient 3 Metastasis in the Suprarenal Gland on the Left Side 320
   Patient 4 Metastasis in the Suprarenal Gland on the Right Side 322
   Patient 5 Metastasized Renal Cell Carcinoma 325
   Patient 6 Restaging after Chemotherapy 327
   Patient 7 Restaging after Tumour Nephrectomy 330
   Patient 8 Recurrence after Tumour Nephrectomy 332
   Patient 9 Metastasized Prostate Carcinoma 334
   Patient 10 Metastasized Prostate Carcinoma 336
   Patient 11 Restaging of a Prostate Carcinoma 338
   Patient 12 Lymph Node Metastasis of a Prostate Carcinoma 340
   Patient 13 First Diagnosis of a Prostate Carcinoma 342
   Patient 14 Restaging of a Prostate Carcinoma 343
   Patient 15 Restaging of a Prostate Carcinoma 345
   Patient 16 Therapy Control for Metastatized Prostate Carcinoma 347
   Patient 17 Staging of a Prostate Carcinoma 349
   Patient 18 Local Recurrence of a Prostate Carcinoma 351
   Patient 19 Lymph Node Metastasis of a Prostate Carcinoma 352
   Patient 20 Lymph Node Metastases of a Prostate Carcinoma 353
   Patient 21 First Diagnosis of a Prostate Carcinoma 354
   Patient 22 Prostatitis ........................ 355
   Patient 23 Prostatitis ........................ 356
   Patient 24 Prostatitis ....................... 357
   Patient 25 Restaging of a Prostate Carcinoma 359

   Patient 26 First Diagnosis of a Prostate Carcinoma 361
   Patient 27 Response Evaluation of a Prostate Carcinoma 362
6.9 References ................................... 363

7 Head and Neck Region .......................... 369
7.1 Head and Neck Tumours ...................... 369
   18F-FDG-PET ................................ 371
   FDG-PET Pitfalls ............................ 373
   PET Indications .............................. 373
7.2 Thyroid Carcinomas .......................... 374
   18F-FDG-PET ................................ 375
7.3 Case Studies .................................. 378
   Patient 1 CUP Tumour ....................... 378
   Patient 2 Tumour Recurrence of an Atypical Laryngeal Carcinoid 380
   Patient 3 Restaging of an Oropharyngeal Carcinoma 381
   Patient 4 Hypopharyngeal Carcinoma 384
   Patient 5 Restaging after Multiple Carcinoma 386
   Patient 6 Auricle Carcinoma ................. 388
   Patient 7 Tonsillar and Laryngeal Carcinoma and Carcinoma of the Base of the Tongue 390
   Patient 8 Recurrence of a Squamous Cell Carcinoma of the Tongue 392
   Patient 9 Tonsillar Carcinoma ............... 394
   Patient 10 Restaging of a Small-Cell Carcinoma of the Left Principal Nasal Cavity 396
   Patient 11 Recurrence of a Vocal Cord Carcinoma 400
   Patient 12 Cerebral Metastatic Spread of a Bronchial Carcinoma 402
   Patient 13 Cystadenocarcinoma of the Lacrimal Sac 405
   Patient 14 Alzheimer’s Disease .............. 406
   Patient 15 Oligodendroglioma on the Left Side 408
   Patient 16 Low-Malignancy Brain Tumour on the Left Side 410
   Patient 17 Hypophyseal Metastasis ........... 413
7.4 References ................................... 415

8 Dermatology ................................. 419
8.1 Malignant Melanoma (MM) ................. 419
   Introduction ................................ 419
   Significance of PET ......................... 421
   Pitfalls ................................. 421
   PET Indications ............................ 421
8.2 Case Studies .................................. 422
   Patient 1 Malignant Melanoma of the Right Thigh 422
   Patient 2 Recurrent Melanoma ............. 424
9 Lymphomas

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.1</td>
<td>Introduction</td>
<td>435</td>
</tr>
<tr>
<td>9.2</td>
<td>Diagnosis</td>
<td>436</td>
</tr>
<tr>
<td>9.3</td>
<td>Case Studies</td>
<td>440</td>
</tr>
<tr>
<td></td>
<td>Patient 1</td>
<td>Follicular Non-Hodgkin's Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Patient 2</td>
<td>Metastasized Non-Hodgkin's Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Patient 3</td>
<td>B-Cell Lymphoma in the Hypopharynx</td>
</tr>
<tr>
<td></td>
<td>Patient 4</td>
<td>B-Cell Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Patient 5</td>
<td>Lymphogranulomatosis, Nodular Sclerosis</td>
</tr>
<tr>
<td></td>
<td>Patient 6</td>
<td>T-Cell Lymphoma of the Cervical Lymph Tract</td>
</tr>
<tr>
<td></td>
<td>Patient 7</td>
<td>B-Cell Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Patient 8</td>
<td>Restaging of Hodgkin's Disease</td>
</tr>
<tr>
<td></td>
<td>Patient 9</td>
<td>Recurrent Hodgkin's Lymphomas</td>
</tr>
<tr>
<td></td>
<td>Patient 10</td>
<td>Chronic Lymphatic Leukaemia</td>
</tr>
<tr>
<td></td>
<td>Patient 11</td>
<td>Restaging of the Multiple Myeloma</td>
</tr>
<tr>
<td>9.4</td>
<td>References</td>
<td>463</td>
</tr>
</tbody>
</table>

10 Oncological Orthopaedics

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.1</td>
<td>Introduction</td>
<td>465</td>
</tr>
<tr>
<td>10.2</td>
<td>Significance of PET</td>
<td>465</td>
</tr>
<tr>
<td></td>
<td>PET Tracers</td>
<td>466</td>
</tr>
<tr>
<td></td>
<td>PET Indications</td>
<td>466</td>
</tr>
<tr>
<td>10.3</td>
<td>Case Studies</td>
<td>467</td>
</tr>
<tr>
<td></td>
<td>Patient 1</td>
<td>Sweat Gland Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Patient 2</td>
<td>Haemangioendothelioma</td>
</tr>
<tr>
<td></td>
<td>Patient 3</td>
<td>Chondrosarcoma</td>
</tr>
<tr>
<td></td>
<td>Patient 4</td>
<td>Medullary Osteosarcoma</td>
</tr>
<tr>
<td></td>
<td>Patient 5</td>
<td>Clear Cell Sarcoma</td>
</tr>
<tr>
<td></td>
<td>Patient 6</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td></td>
<td>Patient 7</td>
<td>Rhabdomyosarcoma of the Left Thigh</td>
</tr>
<tr>
<td></td>
<td>Patient 8</td>
<td>Embryonal Rhabdomyosarcoma</td>
</tr>
<tr>
<td>10.4</td>
<td>References</td>
<td>486</td>
</tr>
</tbody>
</table>

11 Paediatric Oncology

11.1 Introduction | 487 |
11.2 Lymphomas in Childhood | 488 |
11.3 Oncological Orthopaedics in Childhood | 488 |
11.4 Neuroblastomas | 488 |
11.5 Malignant Melanomas | 488 |
11.6 Nesidioblastosis (Congenital Hyperinsulinism) | 489 |
11.7 Case Studies | 490 |
| Patient 1 | Status Post Osseous Sarcoma | 490 |
| Patient 2 | Status Post Mastitis | 491 |
| Patient 3 | Embryonal Rhabdomyosarcoma | 492 |
| Patient 4 | Focal Congenital Hyperinsulinism | 494 |
| Patient 5 | Focal Congenital Hyperinsulinism | 496 |
| Patient 6 | Focal Congenital Hyperinsulinism | 498 |
| Patient 7 | Diffuse Congenital Hyperinsulinism | 500 |
| Patient 8 | Focal Congenital Hyperinsulinism | 502 |
| Patient 9 | Focal Congenital Hyperinsulinism | 504 |
| Patient 10 | Focal Congenital Hyperinsulinism | 506 |
| Patient 11 | Langerhans Cell Histiocytosis | 508 |
| Patient 12 | Langerhans Cell Histiocytosis, Staging and Restaging | 510 |
| 11.8 | References | 514 |

12 CUP Tumours (Cancer of Unknown Primary)

12.1 Introduction | 515 |
12.2 Significance of PET | 516 |
| Cancer of Unknown Primary: Indication for PET/CT | 516 |
| Studies Available | 516 |
| Artefacts, Pitfalls and Metabolic Heterogeneity | 516 |
12.3 Case Studies | 517 |
| Patient 1 | Carcinoma of the Base of the Tongue | 517 |
| Patient 2 | Carcinoma of the Base of the Tongue | 518 |
| Patient 3 | Oropharyngeal Carcinoma | 520 |
| Patient 4 | Cholangiocarcinoma | 523 |
| Patient 5 | Pancreatic Carcinoma | 526 |
| Patient 6 | Carcinoma of the Head of the Pancreas | 528 |
| Patient 7 | Mamma Carcinoma | 530 |
| Patient 8 | CUP Tumour | 533 |
| Patient 9 | Mamma Carcinoma | 536 |
| Patient 10 | Carcinoma of the Base of the Tongue | 538 |
| Patient 11 | Bronchial Carcinoma | 540 |
| Patient 12 | Bronchial Carcinoma | 542 |
| 12.4 | References | 544 |
13 Pitfalls ........................................ 545

13.1 Testicular Carcinoma and
Other Primary Tumours .................... 546
Universal Organ Spectrum of SPT ......... 546

13.2 Physiological Accumulation of FDG .... 547

13.3 False Positive FDG Accumulations in the
Oncological Sense ............................. 547

13.4 Artefacts Due to Technical Factors .... 547

13.5 False Negative PET Findings ........... 547

13.6 Case Studies Secondary Tumours ...... 548
Patient 1 Inflammatory Carcinoma of the
Breast and Papillary Carcinoma of the
Inner Genital Tract .......................... 548
Patient 2 Carcinoma in Situ with Osteoplastic
Metastases 10 years later ................. 551
Patient 3 Recurrence of a Sigmoid Carcinoma,
Compression of the Left Ureter .......... 554
Patient 4 Cervical Carcinoma and
Rectal Carcinoma ............................ 556
Patient 5 Mamma Carcinoma and
Colon Carcinoma ............................ 558
Patient 6 Mamma Carcinoma and
Sigmoid Carcinoma ......................... 560
Patient 7 Thymoma ............................ 561
Patient 8 Prostate Carcinoma and
Colon Carcinoma ............................ 564
Patient 9 Renal Cell and Prostate Carcinoma .... 566
Patient 10 Prostate Carcinoma and
Colon Carcinoma ............................ 568
Patient 11 Carcinoma in Situ of the Rectum
and Bronchial Carcinoma ................. 570
Patient 12 Non-Hodgkin's Lymphoma and
Bronchial Carcinoma ....................... 574
Patient 13 Mamma Carcinoma and
Bronchial Carcinoma ....................... 577
Patient 14 Coecum, Bronchial and
Renal Carcinoma ............................ 579
Patient 15 Mamma, Cervical and
Rectal Carcinoma ............................ 583
Patient 16 Parotid and Colon Carcinoma .... 586

13.7 Case Studies
Physiologically Increased Uptake .......... 589
Patient 17–21 ................................ 589

13.8 Case Studies
Non-Oncological Increased Uptake of
Inflammatory Genesis ..................... 593
Patient 22–31 ................................ 593

13.9 Case Studies
Artefacts .................................... 611
Patient 32–39 ................................ 611

13.10 References ................................ 622

14 Radiotherapeutic Aspects ............... 625

14.1 Introduction ................................ 625

14.2 PET-Assisted Radiotherapy Planning .... 625

14.3 Advantages of PET/CT Integration .... 626

14.4 Fundamentals Governing the Use of PET/CT Data
for Radiotherapy – Bits and Bytes and DICOM .... 626

14.5 Case Studies ............................... 630
Patient 1 Prostate Cancer .................... 630
Patient 2 Oropharyngeal Cancer .......... 632
Patient 3 Breast Cancer ..................... 634
Patient 4 Prostate Cancer .................... 636
Patient 5 Squamous Cell Carcinoma of the
Oral Cavity .................................. 638
Patient 6 Bronchial Cancer ................ 640

14.6 References ............................... 643

15 Nuclear Cardiology ..................... 645
– the Situation in Europe

15.1 Introduction ................................ 645
Development of Nuclear Cardiology
and the Present State ....................... 645
Molecular Cardiac Imaging ............... 647
Fusion Imaging .............................. 649
SPECT and SPECT/CT ..................... 650
MRI and PET/MRI .......................... 652

15.2 Cardiac PET/CT ......................... 652
Coronary Sclerosis .......................... 652
Diabetes Mellitus and Coronary Sclerosis .... 654
Plaque Imaging .............................. 655
Perfusion .................................... 656
Vitality ...................................... 657
Radiation Exposure and
Contrast Medium Safety ................... 657
Artefacts .................................... 658
Invasive Diagnostics, Treatment and
Treatment Monitoring ..................... 658
Prevention .................................. 661
Remarks on the Catalogue for
Further Training for the Specialization in
Nuclear Medicine .......................... 661

15.3 Case Studies ............................... 663
Patient 1 Mild CHD .......................... 663
Patient 2 Status Post Revascularization .... 666
Patient 3 Status Post Anterior Infarction
and Sextuple Bypass ....................... 668
Patient 4 Surprise Finding
of Stem Stenosis ........................... 672

15.4 Reference ................................ 676
# Cardiac PET and PET/CT

---

- **16.1 Introduction**  
- **16.2 Coronary Artery Disease**  
  - Imaging with PET  
  - Accuracy of PET and PET/CT Stress-Rest  
  - Myocardial Perfusion Imaging  
  - Advantages of Myocardial Perfusion Imaging with PET  
  - Hybrid PET/CT Myocardial Perfusion Imaging in Coronary Artery Disease  
- **16.3 Myocardial Viability**  
  - Concepts and Pathophysiology  
  - Assessment of Myocardial Viability  
  - Imaging of Myocardial Perfusion and Metabolism  
  - Clinical Implications of Perfusion Metabolism Imaging  
  - PET/CT vs. Stand-Alone PET  
  - Clinical Indications of Perfusion Metabolism Imaging

---

- **16.4 Vascular Inflammation and Atherosclerosis**  
  - 16.4.1 Large Vessel Vasculitis  
  - 16.4.2 Atherosclerosis and Plaque Imaging

---

- **16.5 Future Developments**

---

- **16.6 References**

---

# Future Trends: Molecular PET

---

- **17.1 Technical Potential and Software Optimization**

---

- **17.2 Molecular PET**
  - Tumour Vitality and Glucose Transporters (GLUT)  
  - Therapeutic and Diagnostic Potential

---

- **17.3 Final Remark**

---

- **17.4 References**

---

# Subject Index